PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
 
AAPS PharmSciTech. Mar 2002; 3(1): 40–47.
Published online Mar 25, 2002. doi:  10.1208/pt030105
PMCID: PMC2750252
Targeted brain delivery of 17β-estradiol via nasally administered water soluble prodrugs
Abeer M. Al-Ghananeem, Ashraf A. Traboulsi, Lewis W. Dittert, and Anwar A. Hussaincorresponding author
Division of Pharmaceutical Sciences, University of Kentucky, 40536 Lexington, Kentucky
Anwar A. Hussain, Phone: (859)-257-5939, Fax: (859)-257-1954, aahuss1/at/pop.uky.edu.
corresponding authorCorresponding author.
Received October 17, 2001; Accepted February 4, 2002.
Abstract
The utility of the nasal route for the systemic delivery of 17β-estradiol was studied using watersoluble prodrugs of 17β-estradiol. This delivery method was examined to determine if it will result in preferential delivery to the brain. Several alkyl prodrugs of 17β-estradiol were prepared and their physicochemical properties were determined. In vitro hydrolysis rate constants in buffer, rat plasma, and rat brain homogenate were determined by high-performance liquid chromatography. In vivo nasal experiments were carried out on rats. Levels of 17β-estradiol in plasma and cerebral spinal fluid (CSF) were determined with radioimunoassay using a gamma counter. The study revealed that the aqueous solubilities of the prodrugs were several orders of magnitude greater than 17β-estradiol with relatively fast in vitro conversion in rat plasma. Absorption was fast following nasal delivery of the prodrugs with high bioavailability. CSF 17β-estradiol concentration was higher following nasal delivery of the prodrugs compared to an equivalent intravenous dose. It was determined that water-soluble prodrugs of 17β-estradiol can be administered nasally. These prodrugs are capable of producing high levels of estradiol in the CSF and as a result may have a significant value in the treatment of Alzheimer's disease.
Full Text
The Full Text of this article is available as a PDF (458K).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
1. Huax Xu, Gouras KG, Greenfield JP, et al. Estrogen reduces neuronal generation of alzheimer β-amyloid peptides. Nature Medicine. 1998;4(4):447–451. doi: 10.1038/nm0498-447. [Cross Ref]
2. Groski RA, Herlan RE, Jacobson CD, Shryne JE, Southane AM. Evidence for the exsistance of sexually dimorphic nucleus in the preoptic area of the rats. J Comp Neurol. 1980;193:529–534. doi: 10.1002/cne.901930214. [PubMed] [Cross Ref]
3. Simpkins JW, Singh M, Bishop J. The potential role for estrogen replacement therapy in the treatment of cognitive decline and neurodegeneration associated with Alzheimer's Disease. Neurobiol. Aging. 1994;15:S195–S197. doi: 10.1016/0197-4580(94)90205-4. [PubMed] [Cross Ref]
4. Bawarshi-Nassar RN, Hussain AA, Crooks PA. Nasal absorption and metabolism of progesterone and 17β-estradiol in the rat. Drug Metab Dispos. 1989;17(3):248–254. [PubMed]
5. Hussain MA, Aungust BJ, Shefter E. Prodrugs for improved oral B-estradiol bioavailability. Pharm Res. 1988;5(1):44–47. doi: 10.1023/A:1015863412137. [PubMed] [Cross Ref]
6. Bawarshi RN. A study of the utility of the nasal route for drug administration. Lexington, KY: University of Kentucky; 1981.
7. Hussain A. Intranasal drug administration delivery. Adv Drug Del Rev. 1998;29:39–49. doi: 10.1016/S0169-409X(97)00060-4. [Cross Ref]
8. Chow HS, Chen Z, Matsuura GT. Direct transport of cocaine from the nasal cavity to the brain following intranasal cocaine administration in rats. J Pharm Sci. 1999;88(8):754–758. doi: 10.1021/js9900295. [PubMed] [Cross Ref]
9. Sakane T, Akizuki M, Yamashita S, et al. Direct drug transport from the rat nasal cavity to the cerebrospinal fluid: the relation to the dissociation of the drug. J Pham Pharmacol. 1994;46(5):378–379.
10. Sakane T, Akizuki M, Yamashita S, et al. Direct drug transport from the rat nasal cavity to the cerebrospinal fluid: the relation to the molecular weight of drugs. J Pharm Pharmacol. 1995;47:379–381. [PubMed]
11. Sakane T, Akizuki M, Yoshida M, et al. Transport of cephalexin to the cerebrospinal fluid directly from the nasal cavity. J Pharm Pharmacol. 1991;43(6):449–51. [PubMed]
12. Kao HD, Traboulsi A, Itoh S, Dittert LW, Hussain A. Enhancement of the systemic and CNS specific delivery of L-dopa by the nasal administration of its water soluble prodrugs. Pharm Res. 2000;17(8):978–984. doi: 10.1023/A:1007583422634. [PubMed] [Cross Ref]
13. Huang CH, Kimura R, Nassar R, Hussain A. Mechanism of nasal absorption of drugs II: absorption of L-tyrosine and the effect of structural modification on its absorption. J Pharm Sci. 1985;74(12):1298–1301. doi: 10.1002/jps.2600741210. [PubMed] [Cross Ref]
14. Huang CH, Kimura R, Nassar R, Hussain A. Mechanism of nasal absorption of drugs I: physicochemical parameters influencing the rate of in situ nasal absorption of drugs in rats. J Pharm Sci. 1985;74(6):608–611. doi: 10.1002/jps.2600740605. [PubMed] [Cross Ref]
15. Hussain A, Schurman P. Thiol esters II: a kinetic study of hydrolysis and aminolysis of propionyl thiocholine iodide and 2-dimethylaminoethiol propionate. J Pharm Sci. 1969;58(6):687–693. doi: 10.1002/jps.2600580608. [PubMed] [Cross Ref]
16. Bruice T, Benkovic S. Bioorganic Mechanism. N. Y.: W. Benjamine, Inc; 1966. pp. 134–134.
Articles from AAPS PharmSciTech are provided here courtesy of
American Association of Pharmaceutical Scientists